1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Bristol Halts HCV Trial Of Inhibitex Nuc Due To Possible Cardiac Toxicity

Bristol had paid $2.5 billion to buy Inhibitex and its Phase II nucleoside polymerase inhibitor in hopes of keeping pace with Gilead in the race to develop the first all-oral combination of direct-acting antivirals for hepatitis C.

Less than a year after acquiring what many perceived as the second-most promising nucleoside polymerase inhibitor in clinical development for hepatitis C, Bristol-Myers Squibb Co. may be in danger of both a lost multi-billion dollar investment and falling out of the race to bring the first all-oral combination of drugs for HCV to market. On Aug. 1, the New Jersey-based pharma announced that it has suspended dosing in a Phase II trial of BMS-986094 due to a “serious safety issue” seen with one of the participants.

A Bristol spokesperson confirmed that the safety issue “presented as heart failure” in an HCV patient who was receiving a 200 mg daily dose of the nucleoside polymerase inhibitor (aka “nuc”) in the trial

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Inclusive By Design: UK Pilots Diversity Plans For Drug & Device Trials

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

US FDA Rare Disease Case Studies Provide Development Models For Sponsors

 
• By Laura Helbling

Sanofi’s Xenpozyme and Sentynyl’s Nulibry are the first two case studies the FDA is using to continue educating rare disease sponsors on best practices.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

More from R&D

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.